Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Want to see ZVRA full AI Analyst Report?
Top Page
Zevra Therapeutics
(NASDAQ:ZVRA)
Select Model
Select Model
Rating:56Neutral
Price Target:
$11.00
▲(3.09% Upside)
Action:ReiteratedDate:04/01/26
The score is driven primarily by mixed financial quality: a strong 2025 profitability headline and improved balance sheet are offset by ongoing operating losses and weak, deteriorating cash flow. Earnings-call commentary is supportive (commercial traction and cash runway) but tempered by variability and clinical/regulatory uncertainties, while technicals are broadly neutral and valuation is helped by a low P/E.
Positive Factors
Commercial traction (MIPLYFFA)
Sustained commercial sales of MIPLYFFA drove the firm to meaningful recurring revenue in 2025, capturing a large share of diagnosed patients and enabling predictable specialty-channel distribution. This entrenches a durable revenue base that supports investment and scale in rare-disease commercialization.
Negative Factors
Weak cash generation
Despite reported net income, operating and free cash flows were negative and worsened in 2025, signaling earnings-quality and working-capital pressures. Persistent cash burn increases the likelihood of future financing, which could dilute shareholders or constrain long-term program funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction (MIPLYFFA)
Sustained commercial sales of MIPLYFFA drove the firm to meaningful recurring revenue in 2025, capturing a large share of diagnosed patients and enabling predictable specialty-channel distribution. This entrenches a durable revenue base that supports investment and scale in rare-disease commercialization.
Read all positive factors
Zevra Therapeutics (ZVRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$601.20M
Dividend YieldN/A
Average Volume (3M)2.44M
Price to Earnings (P/E)6.0
Beta (1Y)0.70
Revenue Growth350.91%
EPS GrowthN/A
CountryUS
Employees59
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.19
Shares Outstanding59,114,850
10 Day Avg. Volume2,552,948
30 Day Avg. Volume2,436,184
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.20
Price to Sales (P/S)4.65
P/FCF Ratio-203.69
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue5.38
Enterprise Value/Gross Profit6.38
Enterprise Value/Ebitda5.80
Forecast
1Y Price Target
$23.71Price Target Upside122.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.46
Revenue Forecast (FY)$144.26M
Zevra Therapeutics Business Overview & Revenue Model
Company Description
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generat...
How the Company Makes Money
Zevra’s primary source of revenue is product sales from its marketed therapy for Niemann-Pick disease type C (NPC). It generates revenue by selling the product through specialty distribution channels to healthcare providers and patients, with net ...
Zevra Therapeutics Earnings Call Summary
Earnings Call Date:Mar 09, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call presented a strong commercial and financial performance for 2025 highlighted by meaningful MIPLYFFA revenue ($87.4M), a full-year net income turnaround ($83.2M), expanding international access via EAP and active EU regulatory engagement. Key operational strengths include growing prescription starts (52 in 2025), 68% U.S. covered lives and a robust cash position ($238.9M). Challenges noted include quarter-to-quarter lumpiness inherent in an ultra-rare indication, elevated SG&A from launch investments, slower-than-desired enrollment/event accrual for the Celiprolol Phase III study (52/150 enrolled; 1/28 events), and some uncertainty around gross-to-net dynamics and regulatory/patent outcomes. On balance, the positives around commercialization, profitability, cash runway, and regulatory progress outweigh the manageable operational and clinical development headwinds.Positive Updates
Strong Full-Year and Quarterly Revenue
2025 net revenue of $106.5M with fourth-quarter net revenue of $34.1M. MIPLYFFA accounted for $87.4M (82% of full-year revenue) and $26.4M (77% of Q4 revenue), demonstrating commercial traction for the lead product.
Negative Updates
Quarter-to-Quarter Variability and Low Patient Counts
Management emphasized lumpiness in revenue and enrollments due to the ultra-rare patient base (one patient can materially affect quarterly results). This creates uncertainty in short-term cadence and predictability.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Full-Year and Quarterly Revenue
2025 net revenue of $106.5M with fourth-quarter net revenue of $34.1M. MIPLYFFA accounted for $87.4M (82% of full-year revenue) and $26.4M (77% of Q4 revenue), demonstrating commercial traction for the lead product.
Read all positive updates
Company Guidance
Management guided that 2026 will be driven by continued U.S. commercial execution and multiple growth drivers while acknowledging quarter-to-quarter variability in an ultra‑rare disease market (one patient can move results); they said they will respond to the EMA’s 120‑day questions within the 90‑day clock‑stop, are pursuing a U.S. patent‑term extension (current orphan exclusivity through 2031), and will pursue further FDA engagement on Celiprolol in H2 2026 after re‑starting DISCOVER (52 of 150 patients enrolled, +8 in Q4, with 1 of 28 events accrued). Management reiterated key 2025 metrics underlying guidance—Q4 net revenue $34.1M (MIPLYFFA $26.4M, EAP $5.6M, OLPRUVA $0.4M, royalties $1.8M), FY net revenue $106.5M (MIPLYFFA $87.4M, EAP $13M, OLPRUVA $0.8M, royalties $5M), Q4 operating expense $23M (R&D $2.6M, SG&A $20.4M), FY operating expense $90.4M (R&D $12.7M, SG&A $77.6M), Q4 net income $12.2M ($0.20 basic/$0.19 diluted) and FY net income $83.2M ($1.40 basic/$1.35 diluted), with a strong balance sheet of $238.9M cash/investments and ~$61.9M debt. They also pointed to commercial access and patient metrics that support growth (161 total MIPLYFFA enrollments since launch; 52 prescription enrollment forms in 2025, 24 in Q4; 113 global EAP patients at year‑end; ~68% of covered lives), while warning EAP ordering patterns, U.S. gross‑to‑net and near‑term sales cadence will be variable and capital will be prioritized to high‑impact initiatives.Zevra Therapeutics Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
63
Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 106.47M | 23.61M | 27.46M | 10.16M | 28.65M |
| Gross Profit | 89.99M | 16.20M | 24.52M | 9.94M | 26.59M |
| EBITDA | 98.71M | -76.40M | -43.54M | -25.53M | -7.89M |
| Net Income | 83.23M | -105.51M | -46.05M | -26.77M | -8.55M |
Balance Sheet | |||||
| Total Assets | 284.73M | 178.13M | 172.33M | 115.34M | 132.94M |
| Cash, Cash Equivalents and Short-Term Investments | 191.01M | 69.50M | 67.74M | 82.85M | 112.35M |
| Total Debt | 63.21M | 60.30M | 43.77M | 18.78M | 1.61M |
| Total Liabilities | 130.07M | 138.46M | 110.46M | 40.22M | 5.82M |
| Stockholders Equity | 154.66M | 39.67M | 61.86M | 75.12M | 127.12M |
Cash Flow | |||||
| Free Cash Flow | -2.43M | -69.67M | -33.83M | -18.81M | 10.34M |
| Operating Cash Flow | -1.60M | -69.67M | -33.53M | -18.72M | 10.44M |
| Investing Cash Flow | 18.13M | -22.16M | -17.39M | -36.72M | -15.52M |
| Financing Cash Flow | 12.06M | 82.11M | 28.46M | 8.35M | 113.11M |
Zevra Therapeutics Technical Analysis
Positive
10.67
Price Trends
9.29
Positive
8.98
Positive
9.53
Positive
Market Momentum
0.26
Negative
67.51
Neutral
88.09
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVRA, the sentiment is Positive. The current price of 10.67 is above the 20-day moving average (MA) of 9.57, above the 50-day MA of 9.29, and above the 200-day MA of 9.53, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 67.51 is Neutral, neither overbought nor oversold. The STOCH value of 88.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZVRA.
Zevra Therapeutics Risk Analysis
Zevra Therapeutics disclosed 44 risk factors in its most recent earnings report. Zevra Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zevra Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $714.35M | -2.68 | -73.34% | ― | ― | 33.41% | |
56 Neutral | $601.20M | 5.95 | 74.63% | ― | 350.91% | ― | |
56 Neutral | $595.39M | -2.11 | -73.00% | ― | -92.83% | -99.35% | |
55 Neutral | $682.13M | -8.29 | -41.94% | ― | 60.24% | 78.37% | |
55 Neutral | $1.28B | -39.78 | -23.29% | ― | ― | 83.13% | |
52 Neutral | $585.63M | -5.95 | -2626.38% | ― | 8.83% | -24.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ZVRA
Zevra Therapeutics
10.07
2.07
25.88%
LXRX
Lexicon Pharmaceuticals
1.63
0.91
126.39%
PRTA
Prothena
10.64
2.56
31.68%
OCGN
Ocugen
1.80
1.04
136.84%
CRVS
Corvus Pharmaceuticals
15.46
11.90
333.66%
SLDB
Solid Biosciences
7.13
2.90
68.56%
Zevra Therapeutics Corporate Events
Business Operations and StrategyLegal ProceedingsM&A TransactionsPrivate Placements and Financing
Zevra Sells SDX Portfolio and Resolves Litigation
Positive
Mar 16, 2026
On March 13, 2026, Zevra Therapeutics agreed to sell its serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million while also resolving ongoing litigation in Delaware tied to a 2019 collaboration...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Zevra Therapeutics Appoints Justin Renz as New CFO
Positive
Mar 9, 2026
On March 4, 2026, Zevra appointed industry veteran Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and principal financial officer, effective March 10, 2026, with an employment package that includes a $520,000 base s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.